Question 1. How many patients have a current diagnosis for Spinal Muscular Atrophy (ICD-10 Code G12.0, G12.1, G12.8 and G12.9) at your trust?
Question 2. How many patients have been treated in the last 4 months (January to April 2025) with the following products:
- Evrysdi (Risdiplam) - total patients
- Spinraza (Nusinersen) - total patients
- Zolgensma (Onasemnogene) - total patients
- Evrysdi (Risdiplam) – new* patients
- Spinraza (Nusinersen) – new* patients
- Zolgensma (Onasemnogene) – new* patients
*new patients are defined as patients who were not treated with any of Spinraza (Nusinersen), Evrysdi (Risdiplam) or Zolgensma (Onasemnogene) in the previous 4-month period (September to December 2024).
Question 3. Of the total patients treated in the last 4 months (January to April 2025) with Evrysdi (Risdiplam), please provide the number of patients that were treated with Spinraza (Nusinersen) in the previous 4 months (September to December 2024).
Question 4. Of the total patients treated in the last 4 months (January to April 2025) with Zolgensma (Onasemnogene), please provide the number of patients that were treated with Spinraza (Nusinersen) in the previous 4 months (September to December 2024).
Question 5. Of the total patients treated in the last 4 months (January to April 2025) with Spinraza (Nusinersen) please provide the number of patients that were treated with Evrysdi (Risdiplam) in the previous 4 months (September to December 2024).
